Lilly Company Products

News

Eli Lilly sues Mochi Health and others

Eli Lilly Sues 4 GLP-1 Telehealth Startups, Escalating War on Knockoff Drugs

Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and weight-loss drugs, Mounjaro and Zepbound.

UPI on MSN · 1d

Eli Lilly sues telehealth companies for selling Mounjaro, Zepbound compounds

Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling compounds of slightly-different versions of Lilly drugs.

Insider Monkey on MSN · 1d

Is Eli Lilly and Company (LLY) the Best Stock That Will Always Grow?

We recently published a list of 10 Best Stocks That Will Always Grow. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best stocks that will always grow.

Reuters3d

Eli Lilly and Co

Lilly sues four compounders over copies of weight-loss drugs Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products ... and the company said it expects to ...

1don MSN

Forget Zepbound: Eli Lilly Has Its Next Billion-Dollar Weight Loss Drug

Eli Lilly ( LLY 0.89%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

Lilly sues four compounders over copies of weight-loss drugs

Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S.

Yahoo Finance1d

Eli Lilly and Company (LLY)

Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jaypirca ...

6don MSN

Eli Lilly says GLP-1 pill for diabetes and weight loss effective in study, plans to seek FDA approval

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

2don MSN

Is Eli Lilly Stock a Buy?

Eli Lilly ( LLY 3.84%) and Novo Nordisk ( NVO 2.01%) were early leaders in the development of GLP-1 agonists, and dominate the market. Research from MarketsandMarkets suggests that annual global sales ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results